Aarti Pharmalabs Ltd

Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Pharmalabs Ltd

₹ 660 -2.03%
23 Jul 4:01 p.m.
aartipharmalabs.com BSE: 543748 NSE: AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Aarti Pharmalabs Ltd, formerly
known as Aarti Organics, was a Wholly
Owned Subsidiary of Aarti Industries
Limited. It got demerged in Oct'22 into
a separately listed entity. Currently, the company is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives, and offers CDMO /CMO services. The company has 6 manufacturing plants and 3 R&D centres.

Website BSE NSE
  • Market Cap ₹ 5,982 Cr.
  • Current Price ₹ 660
  • High / Low ₹ 955 / 584
  • Stock P/E 33.8
  • Book Value ₹ 234
  • Dividend Yield 0.75 %
  • ROCE 10.7 %
  • ROE 8.59 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.88 times its book value
  • Company has a low return on equity of 11.9% over last 3 years.
  • Promoter holding has decreased over last 3 years: -3.12%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
485 458 440 449 506 555 458 538 564 386 418 432 583
405 373 352 353 388 459 364 409 418 293 344 330 470
Operating Profit 80 85 88 96 118 96 94 129 146 93 74 102 113
OPM % 16% 19% 20% 21% 23% 17% 20% 24% 26% 24% 18% 24% 19%
1 0 1 1 2 2 4 5 -2 2 0 2 14
Interest 6 4 4 4 5 5 6 10 7 7 11 13 17
Depreciation 16 17 18 19 19 20 21 23 23 23 25 29 28
Profit before tax 59 64 67 74 96 74 72 101 115 65 39 63 82
Tax % 27% 26% 23% 29% 32% 25% 24% 26% 23% 24% 28% 24% 25%
43 47 52 53 65 55 55 74 88 50 28 48 61
EPS in Rs 4.73 5.20 5.72 5.82 7.20 6.12 6.03 8.16 9.75 5.46 3.08 5.29 6.74
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 1,200 1,945 1,853 2,115 1,819
0 993 1,603 1,467 1,651 1,450
Operating Profit 0 207 342 386 464 369
OPM % 17% 18% 21% 22% 20%
0 3 2 5 10 15
Interest 0 12 21 17 27 47
Depreciation 0 42 63 73 87 104
Profit before tax 0 155 261 300 361 233
Tax % 21% 26% 28% 24% 25%
0 122 193 217 272 175
EPS in Rs 21.35 23.93 30.05 19.27
Dividend Payout % 0% 9% 13% 17% 18%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -2%
TTM: -14%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -3%
TTM: -35%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 26%
1 Year: -29%
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 12%
Last Year: 9%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.25 0.25 45 45 45 45
Reserves -0 1,386 1,513 1,712 1,945 2,079
0 338 215 285 413 754
0 315 470 540 503 603
Total Liabilities 0 2,040 2,244 2,582 2,906 3,482
0 782 926 1,033 1,137 1,525
CWIP 0 187 102 137 374 305
Investments 0 32 87 107 77 194
0 1,038 1,130 1,305 1,319 1,457
Total Assets 0 2,040 2,244 2,582 2,906 3,482

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0 -44 250 216 332 262
0 -139 -158 -215 -414 -431
0 260 -163 10 65 171
Net Cash Flow 0 78 -71 12 -17 2
Free Cash Flow 0 -185 130 18 -112 -186
CFO/OP -11% 91% 71% 85% 84%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 115 84 102 99 117
Inventory Days 272 188 230 190 280
Days Payable 123 106 135 90 146
Cash Conversion Cycle 264 166 197 200 251
Working Capital Days 111 94 110 105 90
ROCE % 19% 16% 17% 17% 11%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
APIs Commercialized (Cumulative)
count ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
CDMO Active Customers
count ・Standalone data
CDMO Total Active Projects (Commercial + Development)
count ・Standalone data
CEP Approvals (Cumulative)
count ・Standalone data
US DMF Approvals (Cumulative)
count ・Standalone data
Xanthine Installed Capacity
MTPA ・Standalone data
Multipurpose Reactor Capacity (API + CDMO)
kL ・Standalone data
R&D Spend as % of API+Int & CDMO sales
% ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
46.30% 46.46% 46.46% 46.46% 46.10% 44.65% 44.29% 43.72% 42.88% 43.10% 43.08% 42.86%
8.45% 8.17% 8.33% 7.07% 7.38% 8.64% 7.36% 7.34% 8.02% 7.69% 8.39% 8.17%
10.51% 9.91% 9.97% 11.47% 11.35% 10.36% 7.53% 7.80% 6.95% 7.66% 7.40% 7.22%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
34.73% 35.45% 35.24% 35.00% 35.17% 36.33% 40.81% 41.12% 42.12% 41.54% 41.10% 41.74%
No. of Shareholders 2,26,2862,15,7962,04,1221,89,0121,85,4361,85,1111,96,3141,87,0391,90,6551,84,4891,79,3731,76,506

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls